Partnering

Purdue Pharma and Alivio Therapeutics, a Boston-based pharmaceutical company focused on targeted disease immunomodulation for treating chronic and acute inflammatory disorders, have formed a $275-million pact ($14.75 million upfront and…

Neurocrine Biosciences, a San Diego, California-based pharmaceutical company developing small molecules for treating neurological and endocrine-related disorders, and Voyager Therapeutics, a Cambridge, Massachusetts company developing gene therapies, have formed a…

Eli Lilly and Company and AC Immune SA, a Lausanne, Switzerland-based biopharmaceutical company, have formed an agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment…

Janssen Pharmaceuticals, one of the pharmaceutical companies of Johnson & Johnson, and argenx, a clinical-stage biotechnology company developing differentiated antibody-based therapies for treating severe autoimmune diseases and cancer, have formed…

Sanofi and Denali Therapeutics, a San Francisco, California-headquartered biopharmaceutical company developing drugs for treating neurodegenerative diseases, have partnered in a deal worth up to $1 billion ($125 million upfront) to…

AstraZeneca, and its global biologics research and development arm MedImmune, have formed a new multi-term agreement with Innate Pharma, a Marseille, France-based biopharmaceutical company, to build on an existing collaboration…

Gilead Sciences and Tango Therapeutics, a Cambridge, Massachusetts-based company developing cancer therapies, have partnered to discover, develop, and commercialize a pipeline of targeted immuno-oncology treatments, in a deal worth up…

Eli Lilly and Company and Dicerna Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical company, have signed a multi-million-dollar pact to develop potential new medicines in the areas of cardio-metabolic disease, neurodegeneration, and…

Roche has partnered with Ionis Pharmaceuticals, a Carlsbad, California-based pharmaceutical company, to develop Ionis’ antisense drug candidate for treating complement-mediated diseases, in a deal worth up to $760 million. The…

Janssen Pharmaceuticals, one of the pharmaceutical companies of Johnson & Johnson, has formed a license and collaboration deal with Arrowhead Pharmaceuticals, a Pasadena, California-based biotechnology company, to develop and commercialize…